United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandra, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING	DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
08/849,525	08/849,525 08/29/1997		GHITA LANZENDORFER	435-WCG	3976	
7590 11/22/2006				EXAM	EXAMINER	
Greenblum & 1950 Roland C		COTTON, ABIO	COTTON, ABIGAIL MANDA			
Reston, VA 20191				ART UNIT	PAPER NUMBER	
				1617	1617	

DATE MAILED: 11/22/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	Applicant(s)		
08/849,525	LANZENDORFER ET AL.	LANZENDORFER ET AL.		
Examiner	Art Unit			
Abigail M. Cotton	1617			

	Abigail M. Cotton	1617	
The MAILING DATE of this communication appe	ars on the cover sheet with the	correspondence add	ress
THE REPLY FILED 07 November 2006 FAILS TO PLACE THIS	APPLICATION IN CONDITION F	OR ALLOWANCE.	
1. The reply was filed after a final rejection, but prior to or on this application, applicant must timely file one of the follow places the application in condition for allowance; (2) a No a Request for Continued Examination (RCE) in compliance time periods:	the same day as filing a Notice of ving replies: (1) an amendment, at tice of Appeal (with appeal fee) in	f Appeal. To avoid aba ffidavit, or other evider compliance with 37 Cl	ce, which FR 41.31; or (3)
a) The period for reply expiresmonths from the mailing b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire to Examiner Note: If box 1 is checked, check either box (a) or (TWO MONTHS OF THE FINAL REJECTION. See MPEP 70	dvisory Action, or (2) the date set forth ater than SIX MONTHS from the mailin b). ONLY CHECK BOX (b) WHEN TH	ng date of the final rejecti	on.
Extensions of time may be obtained under 37 CFR 1.136(a). The date have been filed is the date for purposes of determining the period of extunder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	ension and the corresponding amount thortened statutory period for reply origonal than three months after the mailing date.	t of the fee. The appropri ginally set in the final Offi	ate extension fee ce action; or (2) as
 The Notice of Appeal was filed on A brief in comp filing the Notice of Appeal (37 CFR 41.37(a)), or any exter a Notice of Appeal has been filed, any reply must be filed AMENDMENTS 	nsion thereof (37 CFR 41.37(e)), to	o avoid dismissal of th	is of the date of e appeal. Since
 3. The proposed amendment(s) filed after a final rejection, It (a) They raise new issues that would require further con (b) They raise the issue of new matter (see NOTE below (c) They are not deemed to place the application in bet appeal; and/or (d) They present additional claims without canceling a content of the proposed of the	nsideration and/or search (see NC w); ter form for appeal by materially re	TE below);	
NOTE: (See 37 CFR 1.116 and 41.33(a)). 4. The amendments are not in compliance with 37 CFR 1.12		•	PTOL-324)
5. Applicant's reply has overcome the following rejection(s):		ompliant / interiament (1 102-024).
6. Newly proposed or amended claim(s) would be all non-allowable claim(s).		timely filed amendme	nt canceling the
7. For purposes of appeal, the proposed amendment(s): a) [how the new or amended claims would be rejected is prov The status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: Claim(s) withdrawn from consideration:		ill be entered and an e	xplanation of
AFFIDAVIT OR OTHER EVIDENCE			
8. The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).			
 The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to o showing a good and sufficient reasons why it is necessary 	vercome <u>all</u> rejections under appe and was not earlier presented. S	eal and/or appellant fai See 37 CFR 41.33(d)(1	ls to provide a).
10. The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER	n of the status of the claims after e	entry is below or attach	ed.
 The request for reconsideration has been considered burplease see continuation sheet. 		in condition for allowar	ice because:
12. Note the attached Information Disclosure Statement(s).	PTO/SB/08) Paper No(s).	$\Omega U \wedge$	
13. Other:		Malm	rellar

SREENI PADMANABHAN SUPERVISORY PATENT EXAMINER Application/Control Number: 08/849,525

Art Unit: 1617

Continuation sheet (note # 11)

The request for reconsideration has been considered but does not place the application in condition for allowance. In particular, Applicants argue that there is no motivation to combine the teachings of Evans and Suzuki. The Examiner respectfully disagrees. As set forth in the Final Rejection mailed on September 13, 2006, Evans et al. teaches that antioxidants can be applied to skin to control oxidative damage from UVB radiation, such as in sunburn, whereas Suzuki et al. teaches that alpha-glucosyl rutin has antioxidative effects and can be suitably provided in cosmetic compositions. Thus, one of ordinary skill in the art at the time the invention was made would have found it obvious to provide the alpha-glucosyl rutin in the treatment method of Evans et al, with the expectation of providing a suitable antioxidant effective for reducing controlling oxidative damage caused by exposure to UVB radiation.

Applicants also argue that it is not obvious to combine the teachings of Evans et al. and Suzuki et al, with those of Harrison. The Examiner respectfully disagrees. As discussed in the Final Rejection mailed on September 13, 2006, *Harrison's* teaches that excessive amounts of UVB radiation can lead to immunosuppression of skin cells, and thus it is considered that the population of individuals that has been exposed to excessive UVB radiation, such as those having sunburn, are a population that closely overlaps with and/or is the same as those patients in need of treatment or modulation of the immunosuppression of skin cells induced by the UVB radiation. Accordingly, it is

Art Unit: 1617

considered that the skin treatment method of Evans et al. and Suzuki et al, as evidenced by the entry in *Harrison's*, provides treatment or modulation of immunosuppression of skin cells induced by UVB radiation because the method of Evans et al. and Suzuki et al. teaches the treatment of skin, such as sunburned skin, which has been exposed to excessive UVB radiation, and which is thus likely to have immunosuppression of the skin cells.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Abigail M. Cotton whose telephone number is (571) 272-8779. The examiner can normally be reached on 9:30-6:00, M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreenivasan Padmanabhan can be reached on (571) 272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1617

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

AMC